A New Formulation of Intravenous Paracetamol for Fever Management

NCT02283203 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2016-03-22

No results posted yet for this study

Summary

The efficacy of intravenous paracetamol has never been compared with other drugs for the management of fever due to infections. Available data come from clinical studies conducted in healthy volunteers subject to experimental endotoxemia. The present study compares the efficacy of the new ΑPOTEL Μax® formulation versus placebo for the management of fever of infectious origin.

Conditions

Interventions

DRUG

APOTEL max

The study drug is provided in a form of bag with 100ml final volume and it is directly connected to the infusion device that leads to a catheter already cannulated in one antecubital vein.

DRUG

Placebo

Placebo is provided in a form of bag with 100ml final volume and it is directly connected to the infusion device that leads to a catheter already cannulated in one antecubital vein. Placebo contains water for injection and inactive vehicles.

Sponsors & Collaborators

  • Attikon Hospital

    collaborator OTHER
  • University Hospital of Patras

    collaborator OTHER
  • University Hospital of Crete

    collaborator OTHER
  • Thriasio General Hospital of Elefsina

    collaborator OTHER
  • General Hospital Of Thessaloniki Ippokratio

    collaborator OTHER
  • General Hospital of Chalkida

    collaborator OTHER_GOV
  • Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.

    lead INDUSTRY

Principal Investigators

  • Dimitrios Boumpas, MD, PhD · Attikon Hospital

  • Charalambos Gogos, MD, PhD · University Hospital of Patras

  • George Samonis, MD, PhD · University Hospital of Crete

  • Styliani Sympardi, MD · Thriasio General Hospital of Elefsina

  • Asterios Karagiannis, MD, PhD · University Hospital of Thessaloniki Hippokrateion

  • Nikolaos Tsokos, MD · General Hospital of Halkida

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • Greece

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02283203 on ClinicalTrials.gov